Silver Book Fact

Potential value of pneumonia vaccine

Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4 billion.

Weycker D, Sato R, Strutton D, Edelsberg J, et al. Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years. Vaccine. 2012; 30(36): 5437-44. http://www.sciencedirect.com/science/article/pii/S0264410X12008286

Reference

Title
Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years
Publication
Vaccine
Publication Date
2012
Authors
Weycker D, Sato R, Strutton D, Edelsberg J, et al
Volume & Issue
Volume 30, Issue 36
Pages
5437-44
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Drastic reduction of morbidity from vaccine-preventable disease in 20th century
    In the 20th century, vaccines have reduced the morbidity from vaccine-preventable diseases by as much as 89–100%.  
  • Significant savings from zoster vaccine
    In a cost-effectiveness analysis, investigators estimated the zoster vaccine cost $44,000 per quality-adjusted life year saved for a 70-year-old woman.  
  • Flu vaccine use reduces disease burden
    Use of the LAIV (live attenuated influenza virus) in healthy adults ages 18 to 64 reduced febrile illness by 19% and upper respiratory tract illnesses by 24%. It also…  
  • Staff vaccination in nursing homes reduces mortality rates of residents
    Mortality rates in nursing home residents were 42% lower in facilities with higher staff vaccination coverage compared with control facilities.  
  • Eradication of smallpox has saved 40 million lives worldwide
    Since global vaccination efforts wiped out smallpox disease in 1979, infections in 350 million people have been prevented and 40 million lives have been saved.